Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers

The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such as Trastuzumab. Concurrent targeting of ErbB2 stability with HSP90 inhibitors is synergistic with Trastuzumab, suggesting that pharmacologic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Raja, Srikumar M, Clubb, Robert J, Ortega-Cava, Cesar, Williams, Stetson H, Bailey, Tameka A, Duan, Lei, Zhao, Xiangshan, Reddi, Alagarasamy L, Nyong, Abijah M, Natarajan, Amarnath, Band, Vimla, Band, Hamid
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2011
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047084/
https://ncbi.nlm.nih.gov/pubmed/21088503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.11.2.13959
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars